Nacolomab tafenatox

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNacolomab tafenatox
Drug Alias NameC242 Fab-SEAPNU 214565LS 4565PNV 214565
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionAnti-CA 242ImmunostimulantsInterleukin-2 receptor agonists
TargetsCA 242Interleukin-2 receptor
Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmacia & Upjohn
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmacia & Upjohn +[2
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia